摘要
经典的内源性大麻素(CB)系统由神经信号分子,2-arachidonoyl甘油(2-AG)和叫花生四烯酸乙醇胺(AEA)及其受体(GPCR),g蛋白耦合CB1和CB2构成神经系统(ECS)。然而,假定的,最新的lipid-sensing CB受体最近被确认,包括孤儿GPR55和GPR18受体受到cannabinoid-like分子和与CB体系。CB受体和相关的孤儿GPCRs表达高水平的免疫和/或中枢神经系统(CNS)和调节的神经生理学过程,包括关键事件参与神经炎症。因此,这些受体被确认为新兴治疗靶点的脑部疾病的存在是一个关键的功能,包括多发性硬化症(MS)和阿尔茨海默病(AD)。本文将考虑更广泛的大麻素受体的作用在调节免疫功能总科重点是免疫过程,有助于神经炎症条件。
关键词: 大麻素. 神经的. GPR55. GPR18. 炎症. 神经炎症. 神经退化
Current Drug Targets
Title:The Emerging Role of the Cannabinoid Receptor Family in Peripheral and Neuro-immune Interactions
Volume: 17 Issue: 16
Author(s): Orla Haugh, June Penman, Andrew J. Irving, Veronica A. Campbell
Affiliation:
关键词: 大麻素. 神经的. GPR55. GPR18. 炎症. 神经炎症. 神经退化
摘要: The classical endogenous cannabinoid (CB) system is composed of the endocannabinoid signalling molecules, 2-arachidonoyl glycerol (2-AG) and anandamide (AEA) and their G-protein coupled receptors (GPCR), CB1 and CB2 which together constitutes the endocannabinoid system (ECS). However, putative, novel lipid-sensing CB receptors have recently been identified, including the orphan GPR55 and GPR18 receptors that are regulated by cannabinoid-like molecules and interact with CB system. CB receptors and associated orphan GPCRs are expressed at high levels in the immune and/or central nervous systems (CNS) and regulate a number of neurophysiological processes, including key events involved in neuroinflammation. As such, these receptors have been identified as emerging therapeutic targets for a number of brain disorders in which neuroinflammation is a key feature, including multiple sclerosis (MS) and Alzheimer’s disease (AD). This review will consider the role of the wider cannabinoid receptor superfamily in mediating immune function with a focus on the immune processes that contribute to neuroinflammatory conditions.
Export Options
About this article
Cite this article as:
Orla Haugh, June Penman, Andrew J. Irving, Veronica A. Campbell , The Emerging Role of the Cannabinoid Receptor Family in Peripheral and Neuro-immune Interactions, Current Drug Targets 2016; 17 (16) . https://dx.doi.org/10.2174/1389450117666160112113703
DOI https://dx.doi.org/10.2174/1389450117666160112113703 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems
Current Drug Targets Decreased Regenerative Capacity of Oligodendrocyte Progenitor Cells (NG2-Glia) in the Ageing Brain: A Vicious Cycle of Synaptic Dysfunction, Myelin Loss and Neuronal Disruption?
Current Alzheimer Research Prolyl Peptidases Related to Dipeptidyl Peptidase IV: Potential of Specific Inhibitors in Drug Discovery.
Current Topics in Medicinal Chemistry Editorial [Hot Topic: Anti-Neuroinflammatory Effects of Psychopharmaceuticals: Further than Monoamine Modulators (Guest Editor: Sadayuki Hashioka)]
Mini-Reviews in Medicinal Chemistry Microbiome Regulation of Autoimmune, Gut and Liver Associated Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Therapeutic Targeting of Leukocyte Trafficking Across the Blood-Brain Barrier
Inflammation & Allergy - Drug Targets (Discontinued) Circumscribing the Conformational Peptide Epitope Landscape
Current Pharmaceutical Design Astroglial Connexins as a Therapeutic Target for Alzheimer's Disease
Current Pharmaceutical Design Spots, Blots, Peaks and Chips: Proteomic Approaches in Autoimmune Diseases
Current Pharmaceutical Design The Endocannabinoid System in Ageing: A New Target for Drug Development
Current Drug Targets Contrast Functions of αA- and αB-Crystallins in Cancer Development
Current Molecular Medicine Dehydroepiandrosterone (DHEA): A Steroid with Multiple Effects. Is there Any Possible Option in the Treatment of Critical illness?
Current Medicinal Chemistry Experimental Models of Relapsing-Remitting Multiple Sclerosis: Current Concepts and Perspective
Current Neurovascular Research Therapeutic Potential of Cannabinoids in Neurodegenerative Disorders: A Selective Review
Current Pharmaceutical Design Platelet Activating Factor/Platelet Activating Factor Receptor Pathway as a Potential Therapeutic Target in Autoimmune Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Synaptic Activity-Regulated Wnt Signaling in Synaptic Plasticity, Glial Function and Chronic Pain
CNS & Neurological Disorders - Drug Targets B-Cell Based Gene Therapy for Inducing Tolerance
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Therapeutic Benefits of Regulating Inflammation in Autoimmunity
Inflammation & Allergy - Drug Targets (Discontinued) Mechanisms of CTLA-4-Ig in Tolerance Induction
Current Pharmaceutical Design Molecular Docking Study of a Series of Substituted Xanthone Derivatives as Novel COX-2 Inhibitors Targeting Prostaglandin Endoperoxide Synthase -2
Current Enzyme Inhibition